umbilical vascular endothelial cells huvecs  (ATCC)

Journal: Pharmaceutics

Article Title: Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing †

doi: 10.3390/pharmaceutics17040526

Figure Lengend Snippet: rhMG53 inhibits vascular endothelial cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in HUVEC up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.

Article Snippet: Normal primary human vascular endothelial cells (HUVEC) were purchased from ATCC (Manassas, VA, USA) and grown in F-12K medium containing endothelial cell growth supplement.

Techniques: Migration, Control, Expressing

Journal: Natural Products and Bioprospecting

Article Title: Natural and revolutionary tumor-specific T-cell therapy

doi: 10.1007/s13659-024-00472-w

Figure Lengend Snippet: the natural tumor-specific T-cells could induce specific killing in vitro and vivo. a The treatment scheme of secondary killing test for tumor antigen-specific T-cells; b The secondary killing test of seven single clones and human umbilical vein endothelial cells (HUVEC) and human fetal lung fibroblast 1 (HEL1). It revealed that six clones (F2-H3, A2-B2, A2-G5, A2-H11, A6-D11 and B8-D1) could be induced secondary killing except for the one (B1-D9) and finite cell lines (HUVEC and HEL1); c The treatment scheme of specific killing in mouse; d Quantitation of tumor nodules at lung of targeted activation group (T-F2-H3) and non-targeted group (T-control). It revealed that T-F2-H3 treated mice showed less tumor burden compared with T-Con, in which the tumor nodules were cleared more than 90%,**p < 0.01, t-test. e the HE staining of both groups (T-con and T-F2-H3), which indicated that the tumor nodule of T-F2-H3 group was significantly less than the T-Con group. f the Kaplan–Meier analysis of mice survival, which revealled that the overall survival of T-F2-H3 was greatly extended compared with control cohort (median survival: 76 days vs 30 days, p = 0.0018)

Article Snippet: The lung cancer cell (A549), human umbilical vein vascular endothelial cells (HUVEC) and human fetal lung fibroblast 1 (HEL1) were harvested from ATCC, which had been authenticated and free of mycoplasma, and together with these single clones were cultured in DMEM completed medium (DMEM + 10% FBS + 1% P/S) at 37°C 5%CO 2 cell incubators.

Techniques: In Vitro, Clone Assay, Quantitation Assay, Activation Assay, Control, Staining